Acuta Capital Partners, LLC Fulcrum Therapeutics, Inc. Transaction History

Acuta Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$5.01 - $8.35 $175,350 - $292,250	-35,000 Reduced 15.91%	185,000 $1.35 Million
Q3 2022 Nov 14, 2022	BUY	$4.92 - $9.1 $98,400 - $182,000	20,000 Added 10.0%	220,000 $1.78 Million
Q4 2021 Feb 14, 2022	SELL	$14.0 - $28.44 $1.72 Million - $3.48 Million	-122,500 Reduced 37.98%	200,000 $3.54 Million
Q3 2021 Nov 15, 2021	SELL	$7.28 - $30.97 $2.05 Million - $8.72 Million	-281,574 Reduced 46.61%	322,500 $9.1 Million
Q2 2021 Aug 16, 2021	SELL	$8.09 - $12.0 $149,066 - $221,112	-18,426 Reduced 2.96%	604,074 $6.33 Million
Q1 2021 May 17, 2021	SELL	$10.94 - $15.32 $656,400 - $919,200	-60,000 Reduced 8.79%	622,500 $7.33 Million
Q4 2020 Feb 16, 2021	BUY	$7.84 - $13.4 $2.36 Million - $4.03 Million	301,000 Added 78.9%	682,500 $7.99 Million
Q3 2020 Nov 16, 2020	BUY	$7.22 - $20.7 $2.75 Million - $7.9 Million	381,500 New	381,500 $3.03 Million

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $237M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.